Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerDavid Miles, Gilles Romieu, Luc Dirix et al.|Journal of Clinical Oncology|2010Cited by 887